AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Dibaglim M 1mg/500mg Tablet SR

Prescription Icon
Prescription Required

Marketer

Kasdap Healthcare Pvt Ltd

Salt Composition

Glimepiride (1mg) + Metformin (500mg)

Overview Dibaglim M 1mg/500mg Tablet SR

Glimepiride/Metformin extended-release tablets (1mg/500mg) are classified as antidiabetic medications. This combination therapy treats type 2 diabetes in adults by regulating blood glucose. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage is determined and adjusted by your physician based on your blood sugar response. Continuous use is crucial, even with controlled blood sugar, as discontinuation without medical supervision can elevate glucose levels, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. Remember, this medication complements a comprehensive diabetes management plan encompassing diet, exercise, and weight management as directed by your healthcare provider. Lifestyle adjustments significantly impact diabetes control. Hypoglycemia (low blood sugar) is a common side effect. Learn to recognize its symptoms – sweating, dizziness, headache, tremors – and how to manage them. Maintain regular mealtimes and carry a rapid-acting glucose source, like sugary snacks or juice. Alcohol consumption raises hypoglycemia risk and should be avoided. Other possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain is also a potential consequence. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe kidney or liver impairment. Disclose any history of heart disease to your physician prior to commencing treatment. Pregnant or breastfeeding individuals should seek medical advice before use. Regular blood glucose monitoring and periodic blood tests (to assess blood cell counts and liver function) are recommended.

Uses of Dibaglim M 1mg/500mg Tablet SR

Managing type 2 diabetes

Major Benefits of Dibaglim M 1mg/500mg Tablet SR:

Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment length. Ingest the entire tablet without chewing, crushing, or fracturing. Consume Dibaglim M 1mg/500mg Extended-Release tablets with food.

Common Side effects of Dibaglim M 1mg/500mg Tablet SR:

  • Headache
  • Hypoglycemia (low blood glucose level)
  • Nausea
  • Diarrhea

How to use Dibaglim M 1mg/500mg Tablet SR:

Consume this medication precisely as prescribed by your physician, adhering to the recommended dosage and treatment schedule. Ingest the entire tablet without chewing, crushing, or fracturing it. The Dibaglim M 1mg/500mg sustained-release tablet should be administered with a meal.

How Dibaglim M 1mg/500mg Tablet SR works:

Dibaglim M 1mg/500mg Extended-Release tablets combine glimepiride and metformin, two antidiabetic agents. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion to reduce blood glucose levels. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose absorption, and enhancing insulin sensitivity.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol concurrently with Dibaglim M 1mg/500mg SR tablets is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The extended-release Dibaglim M 1mg/500mg tablet may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against any possible risks prior to prescribing. Medical advice is recommended.

Breast feedingBreast feedingUNSAFE

Extended-release Dibaglim M 1mg/500mg tablets are contraindicated for breastfeeding mothers. Evidence indicates potential infant harm from the medication.

DrivingDrivingCAUTION

Driving may be impaired by excessively high or low blood sugar levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Exercise caution when prescribing Dibaglim M 1mg/500mg SR tablets to individuals with impaired kidney function; dosage modification may be necessary. Consult a physician for guidance. The use of Dibaglim M 1mg/500mg SR tablets is contraindicated in patients exhibiting severe kidney disease. Close monitoring of renal function is recommended during treatment.

LiverLiverCAUTION

Exercise caution when prescribing Dibaglim M 1mg/500mg SR tablets to patients with hepatic impairment; dosage modification may be necessary. Consult a physician before administering. For patients exhibiting mild to moderate liver disease, initiate treatment with a reduced Dibaglim M 1mg/500mg SR tablet dosage; avoid use in those with severe liver dysfunction.

What if you forget to take Dibaglim M 1mg/500mg Tablet SR :

Should you forget a dose of Dibaglim M 1mg/500mg Extended-Release Tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Dibaglim M 1mg/500mg Tablet SR

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Dibaglim M 1mg/500mg Tablet SR

Store this medication in its original, tightly closed container, following the storage instructions on the label or packaging. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Dibaglim M 1mg/500mg Tablet SR can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA). This rare but potentially harmful side effect is more likely in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If you experience these symptoms, discontinue use and seek immediate medical attention.
Dibaglim M 1mg/500mg SR tablets combine glimepiride and metformin to manage type 2 diabetes mellitus in adults. This combination improves blood glucose control when used with diet and exercise. Glimepiride stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for type 1 diabetes.
Dibaglim M 1mg/500mg Tablet SR may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, and headache. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Prolonged use of Dibaglim M 1mg/500mg Tablet SR can lead to vitamin B12 deficiency by impairing its absorption. This deficiency, if left untreated, may result in anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and ataxia), urinary issues, and cognitive changes. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Dibaglim M 1mg/500mg SR Tablets can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed or delayed meals, alcohol consumption, excessive exercise, or concurrent use of other antidiabetic medications. Regular blood sugar monitoring is crucial. Always carry a fast-acting sugar source, such as glucose tablets, honey, or fruit juice.
Combining Dibaglim M 1mg/500mg SR tablets and alcohol is unsafe. Alcohol can worsen the drug's blood sugar-lowering effects, potentially causing hypoglycemia and increasing the risk of lactic acidosis.
Dibaglim M 1mg/500mg Tabl...
90
MRP 110
18% off